Tandem Capital Management Corp ADV Invests $450,000 in argenex SE $ARGX

Tandem Capital Management Corp ADV bought a new position in argenex SE (NASDAQ:ARGX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 817 shares of the company’s stock, valued at approximately $450,000.

Several other hedge funds have also recently modified their holdings of ARGX. Park Avenue Securities LLC lifted its holdings in shares of argenex by 6.4% in the first quarter. Park Avenue Securities LLC now owns 1,804 shares of the company’s stock worth $1,068,000 after buying an additional 109 shares in the last quarter. Handelsbanken Fonder AB raised its stake in argenex by 13.1% during the first quarter. Handelsbanken Fonder AB now owns 38,050 shares of the company’s stock valued at $22,520,000 after purchasing an additional 4,403 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in argenex by 215.8% during the first quarter. Assenagon Asset Management S.A. now owns 110,390 shares of the company’s stock valued at $65,336,000 after purchasing an additional 75,435 shares in the last quarter. Janney Montgomery Scott LLC raised its stake in argenex by 41.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,141 shares of the company’s stock valued at $675,000 after purchasing an additional 335 shares in the last quarter. Finally, Sowell Financial Services LLC purchased a new stake in argenex during the first quarter valued at $332,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Up 0.2%

ARGX stock opened at $798.94 on Thursday. argenex SE has a twelve month low of $510.05 and a twelve month high of $807.91. The stock has a market capitalization of $48.90 billion, a price-to-earnings ratio of 40.97, a price-to-earnings-growth ratio of 0.87 and a beta of 0.46. The firm’s fifty day simple moving average is $714.80 and its two-hundred day simple moving average is $624.77.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating analysts’ consensus estimates of $2.84 by $0.90. The business had revenue of $866.79 million for the quarter, compared to analysts’ expectations of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. As a group, equities research analysts expect that argenex SE will post 3.13 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ARGX shares. Piper Sandler upped their price target on shares of argenex from $750.00 to $820.00 and gave the company an “overweight” rating in a research note on Tuesday, August 26th. Wells Fargo & Company upped their price target on shares of argenex from $741.00 to $756.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. Royal Bank Of Canada started coverage on shares of argenex in a research note on Monday, August 25th. They set an “outperform” rating and a $850.00 price target on the stock. Stifel Nicolaus set a $882.00 price target on shares of argenex in a research note on Thursday, September 18th. Finally, Zacks Research raised shares of argenex from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 22nd. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $802.90.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.